Conference Reports for NATAP

Back

Conference on Retroviruses and Opportunistic Infections San Francisco, CA March 9-12 2025     HIV Treatment, Long-Acting, New Drug Development, PrEP   Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir - (03/14/25)   HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial - (03/13/25)   Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option - (03/13/25)   ViiV HEALTHCARE'S INVESTIGATIONAL BROADLY NEUTRALISING ANTIBODY - N6LS - SUCCESSFULLY MAINTAINS VIRAL SUPPRESSION IN LONG-ACTING TREATMENT OF HIV - (03/13/25)   VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study - (03/13/25)   Switch to DOR/ISL (100/0.25 mg) QD from Oral ART: an Open-Label Phase 3 Study in Adults with HIV-1 - (03/13/25)   Switch to DOR/ISL (100/0.25 mg) QD from BIC/FTC/TAF: a Blinded Phase 3 Study in Adults with HIV-1 - (03/13/25)   Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay - (03/13/25)   Randomized trial of Cabotegravir and Rilpivirine Long-acting in Africa (CARES):Week 96 Result - (03/13/25)   Long-acting Cabotegravir PrEP Uptake and Persistence in a Large U.S. Healthcare System - (03/13/25)   Preliminary Efficacy for HPTN 094: 26-week RCT of Integrated Strategies for People Who Inject Drugs - (03/13/25)   ImPrEP CAB Brasil: Enhancing PrEP Coverage with CAB-LA in Young Key Populations - (03/13/25)   Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir - (03/13/25)   Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1 - (03/12/25)   5'Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART (NSV) - (03/12/25)   Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor - (03/12/25)   Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor - (03/12/25)   Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study published - (03/12/25)   ViiV HEALTHCARE SHOWCASES LEADERSHIP IN LONG-ACTING INJECTABLES INNOVATION AT CROI 2025 WITH DATA ON THIRD-GENERATION INTEGRASE INHIBITOR (INSTI) AND HIGHLY POTENT CAPSID INHIBITOR AGAINST HIV-1 - (03/12/25)   First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet - (03/12/25)   Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase 2 Week 26 Primary Outcome - (03/12/25)   Update on Merck's Late-Stage HIV Pipeline - (03/11/25)   Update on Update on the Long-Acting HIV Treatment and Prevention Pipeline - (03/11/25)   MK-8527 PK/PD Threshold and Phase 2 Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis - (03/11/25)   Current status of LA/ER Cabotegravir (CAB) and Rilpivirine including pipeline report - (03/11/25)   In Vitro Resistance Profile for GS-1720, a Potent Once-Weekly Oral INSTI in Clinical Development - (03/11/25)   Modeling Accurately Predicts Efficacious Islatravir QW Dose with no Lymphocyte and CD4 Changes - (03/11/25)   Pharmacokinetic Modeling of Missed Dose Scenario of Oral Weekly Islatravir Plus Lenacapavir - (03/11/25)   Bictegravir + Lenacapavir: Baseline and Week 48 Resistance Analyses in ARTISTRY-1 Phase 2 - (03/11/25)   Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks - (03/11/25)   Clinical Outcomes Among Virologically Suppressed Women Receiving CAB+RPV LA in the OPERA Cohort - (03/11/25)   Long-term CAB+RPV LA Effectiveness in Virologically Suppressed Individuals in the OPERA Cohort - (03/11/25)   Outcomes on Cabotegravir + Rilpivirine in Suppressed People with HIV (PWH) in TRIO Health US Cohort - (03/11/25)   Aging, Comorbidities   Letermovir for CMV Suppression Improves Immunologic and Functional Aging Outcomes in Treated HIV - (03/14/25)   Mitochondrial DNA Variation and Physical Function among Men with and without HIV - (03/12/25)   Risk of Incident Hypertension with Common Antiretroviral Agent Combinations in the OPERA Cohort - (03/11/25)   Renal Outcomes in People With HIV-1 and Renal Impairment Treated With B/F/TAF in Randomized Trials - (03/11/25)   No Increased Risk for Hypertension with CAB-LA Compared to TDF/FTC for PrEP: Results from HPTN 084 - (03/11/25)   DoxyPEP   DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC...."early uptake of DoxyPEP was minimal, yet a majority of PWH were DoxyPEP eligible" - (03/15/25)   High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation - (03/15/25)   The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco, Low Adherence - (03/15/25)   Young Black Sexually Minoritized Men Living with HIV, Substance Use, and Syphilis Want Doxy-PEP - (03/11/25)   Characteristics of Breakthrough Chlamydia Cases among Cisgender Women Assigned to Doxycycline Postexposure Prophylaxis - (03/11/25)   Post-Exposure Prophylaxis With Doxycycline (DoxyPEP) in a Cohort of High-Risk MSM: The PRIDOX Study - (03/11/25)   Antimicrobial Resistance of N. gonorrhoeae at a Community-Based Sexual Health Clinic, 2023-2024 - (03/11/25)   Hepatitis, Liver   Safety and Efficacy of Glecaprevir/Pibrentasvir for 8 Weeks for Treatment of Acute Hepatitis C Virus Infection in People Living with HIV - (03/11/25)   Impact of HIV Infection on the Dynamics of Liver Stiffness After HCV Cure - (03/11/25)   "HIV Cure", Viral Control   AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques - (03/13/25)   Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option - (03/13/25)   The RIO trial: A Randomised Placebo-Controlled Study of 2 LS-bNAbs (3BNC-117-LS & 10-1074-LS) in People Treated in Early HIV - (03/12/25)   Evaluation of 2 Broadly Neutralizing Antibodies Plus Vesatolimod in Early-Treated South African Women With HIV-1 During Analytical Treatment Interruption - (03/12/25)   The Barrier to HIV-1 Escape from Broadly Neutralizing Antibodies Varies Between Different HIV-1 Isolates - (03/11/25)